Eagle Pharmaceuticals Competitors

Prestige Consumer Healthcare (NYSE:PBH) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both consumer discretionary companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, analyst recommendations, earnings, institutional ownership and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Prestige Consumer Healthcare and Eagle Pharmaceuticals, as provided by MarketBeat.com.

Prestige Consumer Healthcare presently has a consensus price target of $87.60, suggesting a potential upside of 93.72%. Eagle Pharmaceuticals has a consensus price target of $46.00, suggesting a potential upside of 3.91%. Given Prestige Consumer Healthcare's stronger consensus rating and higher possible upside, equities research analysts plainly believe Prestige Consumer Healthcare is more favorable than Eagle Pharmaceuticals.

Risk and Volatility

Prestige Consumer Healthcare has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Earnings and Valuation

This table compares Prestige Consumer Healthcare and Eagle Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Prestige Consumer Healthcare has higher revenue and earnings than Eagle Pharmaceuticals. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

95.1% of Eagle Pharmaceuticals shares are held by institutional investors. 1.2% of Prestige Consumer Healthcare shares are held by insiders. Comparatively, 21.1% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Prestige Consumer Healthcare and Eagle Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Prestige Consumer Healthcare beats Eagle Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Institutional and Insider Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.1% of Eagle Pharmaceuticals shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by insiders. Comparatively, 21.1% of Eagle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Dicerna Pharmaceuticals and Eagle Pharmaceuticals' net margins, return on equity and return on assets.

Volatility and Risk

Dicerna Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Dicerna Pharmaceuticals and Eagle Pharmaceuticals, as reported by MarketBeat.

Dicerna Pharmaceuticals currently has a consensus target price of $39.1429, suggesting a potential upside of 35.16%. Eagle Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 3.91%. Given Dicerna Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Dicerna Pharmaceuticals is more favorable than Eagle Pharmaceuticals.

Valuation & Earnings

This table compares Dicerna Pharmaceuticals and Eagle Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Eagle Pharmaceuticals has higher revenue and earnings than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Eagle Pharmaceuticals beats Dicerna Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional & Insider Ownership

67.1% of Zentalis Pharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of Eagle Pharmaceuticals shares are held by institutional investors. 21.1% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Zentalis Pharmaceuticals and Eagle Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Zentalis Pharmaceuticals and Eagle Pharmaceuticals, as reported by MarketBeat.com.

Zentalis Pharmaceuticals presently has a consensus target price of $56.4286, suggesting a potential upside of 11.34%. Eagle Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 3.91%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Zentalis Pharmaceuticals is more favorable than Eagle Pharmaceuticals.

Valuation and Earnings

This table compares Zentalis Pharmaceuticals and Eagle Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Eagle Pharmaceuticals has higher revenue and earnings than Zentalis Pharmaceuticals.

Summary

Eagle Pharmaceuticals beats Zentalis Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

NGM Biopharmaceuticals (NASDAQ:NGM) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Institutional & Insider Ownership

49.6% of NGM Biopharmaceuticals shares are held by institutional investors. Comparatively, 95.1% of Eagle Pharmaceuticals shares are held by institutional investors. 50.4% of NGM Biopharmaceuticals shares are held by insiders. Comparatively, 21.1% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares NGM Biopharmaceuticals and Eagle Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Eagle Pharmaceuticals has higher revenue and earnings than NGM Biopharmaceuticals. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

NGM Biopharmaceuticals has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for NGM Biopharmaceuticals and Eagle Pharmaceuticals, as reported by MarketBeat.com.

NGM Biopharmaceuticals presently has a consensus target price of $39.1111, suggesting a potential upside of 49.56%. Eagle Pharmaceuticals has a consensus target price of $46.00, suggesting a potential upside of 3.91%. Given NGM Biopharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe NGM Biopharmaceuticals is more favorable than Eagle Pharmaceuticals.

Profitability

This table compares NGM Biopharmaceuticals and Eagle Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Eagle Pharmaceuticals beats NGM Biopharmaceuticals on 8 of the 15 factors compared between the two stocks.

Eagle Pharmaceuticals (NASDAQ:EGRX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Insider and Institutional Ownership

95.1% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 74.2% of Madrigal Pharmaceuticals shares are held by institutional investors. 21.1% of Eagle Pharmaceuticals shares are held by company insiders. Comparatively, 41.9% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Eagle Pharmaceuticals and Madrigal Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Eagle Pharmaceuticals has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Eagle Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Eagle Pharmaceuticals and Madrigal Pharmaceuticals, as provided by MarketBeat.

Eagle Pharmaceuticals presently has a consensus price target of $46.00, suggesting a potential upside of 3.91%. Madrigal Pharmaceuticals has a consensus price target of $167.60, suggesting a potential upside of 34.33%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Eagle Pharmaceuticals.

Profitability

This table compares Eagle Pharmaceuticals and Madrigal Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Eagle Pharmaceuticals beats Madrigal Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Eagle Pharmaceuticals (NASDAQ:EGRX) and Axsome Therapeutics (NASDAQ:AXSM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Profitability

This table compares Eagle Pharmaceuticals and Axsome Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Eagle Pharmaceuticals and Axsome Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Eagle Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Eagle Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500.

Insider and Institutional Ownership

95.1% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 63.6% of Axsome Therapeutics shares are held by institutional investors. 21.1% of Eagle Pharmaceuticals shares are held by company insiders. Comparatively, 26.0% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings for Eagle Pharmaceuticals and Axsome Therapeutics, as provided by MarketBeat.

Eagle Pharmaceuticals presently has a consensus price target of $46.00, suggesting a potential upside of 3.91%. Axsome Therapeutics has a consensus price target of $152.6667, suggesting a potential upside of 185.68%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Eagle Pharmaceuticals.

Summary

Eagle Pharmaceuticals beats Axsome Therapeutics on 8 of the 13 factors compared between the two stocks.